Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Appears that Brilicidin is still being researched for Covid-19 remediation possibilities. This report was recently updated Here:
https://www.biorxiv.org/content/10.1101/2021.11.04.467344v1.full.pdf+html
Yanmei Hu, Hyunil Jo, William F. DeGrado, View ORCID ProfileJun Wang
doi: https://doi.org/10.1101/2021.11.04.467344
Now published in Journal of Medical Virology doi: 10.1002/jmv.27616
INTRODUCTION Seven coronaviruses are known to infect human beings. Human coronavirus (HCoV)-229E, -NL63, -OC43 and -HKU1 account for 15~30% cases of common cold worldwide 1,
while severe acute respiratory syndrome coronavirus (SARS-CoV) 2, Middle East Respiratory Syndrome (MERS-CoV) 3, and severe acute respiratory syndrome
coronavirus 2 (SARS-CoV-2)-the causative agent of COVID-19 4, are three highly pathogenic human coronaviruses that cause acute severe respiratory syndrome.
As the third coronavirus that causes severe respiratory disease, SARS-CoV-2 associated COVID19 has led to more than 211 million infections and over 4.4
million deaths worldwide, and more than 37 million infections and over 627 thousand deaths in the U.S. alone as of Aug 21, 2021 5. Currently, two mRNA vaccines
are authorized for COVID-19: BNT162b2 (Pfizer, Inc., and BioNTech) and mRNA-1273 (ModernaTX, Inc.), and a third single-dose COVID-19 vaccine JNJ-78436735 (Johnson & Johnson) was
issued for Emergency Use Authorization. Although vaccine continues to be a mainstay for viral prophylaxis, the efficacy of vaccine might be compromised with emerging
variants such as the delta variant 6-8. For this reason, small molecular antiviral drugs are important complements of vaccines to help combat pandemics. Host defense
peptides (HDPs), also called antimicrobial peptides (AMPs), are typically small peptides (12-50 amino acids) that are expressed in neutrophils and mucosa and serve as
the first line of defense against foreign pathogens 9. HDPs have been extensively explored as antibiotics 10, antivirals 11, antifungals 12 and anticancer agents 13.
Most HDPs share an amphiphilic structure with a positively charged face and a hydrophobic face 14. It is proposed that HDPs disrupt bacterial cell
membranes by .CC-BY 4.0 International licenseavailable under a(which was not certified by peer review) is the author/funder, who has granted bioRxiv
a license to display the preprint in perpetuity. It is made The copyright holder for this preprintthis version
posted November 5, 2021. ; https://doi.org/10.1101/2021.11.04.467344doi: bioRxiv preprint
interacting with the negatively charged phospholipid headgroups 15-17. Brilacidin is a small synthetic HDP mimetic 18, and
has potent antibacterial activity against both Gram-positive and Gram-negative bacteria, and is currently in Phase 2 clinical
trials (Clinical Trials NCT01211470, NCT020388, and NCT02324335). The antibacterial mechanisms of action of brilacidin include both
membrane disruption and immunomodulation 19, 20. Brilacidin is also in clinical trial (NCT04784897) as a SARS-CoV-2 antiviral drug
candidate for hospitalized COVID-19 patients. A recent study showed that brilacidin exhibited potent inhibitory effect on SARS-CoV-2
replication (EC50=0.565 µM/CC50=241 µM), and the proposed mechanism of action is through disrupting viral integrity, thereby blocking viral
entry 21. However, the effect of brilacidin on host cell and the antiviral activity of brilacidin against other HCoVs have not been
investigated. In this work, we showed that brilacidin inhibits SARS-CoV-2 pseudovirus entry into multiple cell lines. However, acetyl brilacidin
had no inhibition on SARS-CoV-2 pseudovirus entry, and heparin, a heparan sulfate proteoglycans (HSPGs) mimetic, diminished the inhibitory
activity of brilacidin. This result suggests that brilacidin has an additional mechanism of action by binding to HSPGs on the host cell,
thereby blocking viral attachment. HSPGs have been reported as an attachment factor for SARS-CoV-2
China's zero-Covid strategy 'won't work' against omicron, says epidemiologist https://www.cnbc.com/2022/02/07/chinas-zero-covid-policy-will-not-work-with-omicron-epidemiologist.html?__source=iosappshare%7Ccom.apple.UIKit.activity.CopyToPasteboard
A new virus will always look for ways to find new hosts and spread itself and live. It is the same as a dandelion seed finding the wee crack in the concrete.
*Mink farms have already spawned three variants – in Denmark, France, and the United States. As such, they are a proven source of multiple novel virus variants that may compromise human vaccine effectiveness. or increase human virus virulence or transmissibility. Mink are a top candidate as the “missing link” between bats which most scientists believe to be the original source of COVID, and people according to the World Health Organization.*
https://www.einpresswire.com/article/562371511/rep-nancy-mace-shepherds-sweeping-ban-on-mink-farming-to-passage-citing-cruelty-and-contagion-risks
A related factor that has to be considered is antibody-dependent enhancement of infection (ADE) by vaccines. This is best known with dengue, RSV and measles vaccines. It occurs when non-neutralizing antibodies actually facilitate attachment of wild viruses to cells, thereby producing more severe illness in vaccinated individuals than in unvaccinated individuals. Iwasaki and Yang suggested that this is a potential danger with Covid-19 vaccines. (Nat Rev Immunol 2020;20:339) It may, therefore, be of vital importance that Yahi and colleagues have shown that vaccines directed against the original Wuhan/D614G strain produce antibodies that fail to neutralize Delta variants and allow the attachment of Delta viruses to cells. (Yahi et al, Journal of Infection 2021;16:58, August 16) Some of the breakthrough illnesses caused by the Delta variant in vaccinated individuals may be the result of this interaction.
https://www.bmj.com/content/374/bmj.n2029/rr
https://www.the-sun.com/health/4600486/cancer-cured-turbocharge-blood-immune-cells/
CANCER patients have been cured after medics turbocharged their blood’s immune cells in a lab.
Two adults withLeukaemia have been in remission since 2010 after Car-T therapy. It involves removing blood and genetically modifying its white cells so they target cancer.
The resulting Car-T cells are re-injected in a type of immunotherapy which uses the body’s immune system to attack tumors.
Levels of the cells in the two cured patients remain high.
Dr Carl June, of the University of Pennsylvania, US, said: “Based on these results, we can conclude that Car-T cells can cure Leukaemia.
“These cells continued to demonstrate tumour-killing characteristics.”
Patient Doug Olsen said medics could not find any cancer after a few weeks. He said: “I knew the doctors weren’t sure but I was pretty convinced that I was done with cancer.”
The NHS offers Car-T to some children with leukaemia and adults with lymphoma.
It warns the therapy can make the immune system over-react or trigger side effects such as fever, vomiting or breathing difficulties.
Why do some people get Covid when others don't? Here’s what we know so far https://www.cnbc.com/2022/02/03/why-do-some-people-get-covid-while-others-dont.html?__source=iosappshare%7Ccom.apple.UIKit.activity.CopyToPasteboard
While vaccination lowers the risk of death and hospitalization, it may not lower the risk of catching Covid and it does not eliminate the risk of dying from Covid, even in the triple vaccinated.
Therapeutics are still needed.
Israel a country where Covid vaccination is almost universal. Below are reports from January 2022.
"The Health Ministry updated its coronavirus figures on Friday, revealing that nearly 70,000 Israelis tested positive for COVID-19 the day before, with the number of patients in serious condition climbing to 638.
Total active cases rose to 427,023 and 1,758 Israelis were hospitalized in all, with 123 of them on ventilators.
At least 9,867 medical staff were sidelined after contracting COVID themselves, including 1,379 doctors and 2,916 nurses, the ministry said."
https://www.timesofisrael.com/israel-sees-70000-new-covid-cases-with-638-hospitalized-in-serious-condition/
"On Wednesday, the Israeli government reported that a record 11,978 new infections were registered the day before. That beats the previous high of 11,345 infections in a single day set Sept. 2 during the Delta variant wave."
"Israel also is on the cusp of making available drugs that could help people in at-risk groups avoid severe infections."
"There is no control of the Omicron wave,” Sharon Alroy-Preis, the Israeli Health Ministry’s top public health official, said on Israel’s Channel 13 this week."
"The Health Ministry updated its coronavirus figures on Friday, revealing that nearly 70,000 Israelis tested positive for COVID-19 the day before, with the number of patients in serious condition climbing to 638.
Total active cases rose to 427,023 and 1,758 Israelis were hospitalized in all, with 123 of them on ventilators.
At least 9,867 medical staff were sidelined after contracting COVID themselves, including 1,379 doctors and 2,916 nurses, the ministry said."
https://www.latimes.com/world-nation/story/2022-01-05/israel-all-time-high-covid-infections-fourth-vaccine
Since the vaccines do not eliminate deaths or hospitalization, what will we do for the next variant which may be more deadly than Omicron. Are we going to give a 4th vaccine like the Israelis? Will it make sense to give the 5th, 6th or 7th vaccine booster?
IMO this is the time to develop therapeutics.
The Exposé explains:19
“What we can see from the above is that the immune system performance for adults aged between 18 and 59 has deteriorated to the worst levels yet since they were given the COVID-19 vaccine.
Whilst the immune system performance of everyone over the age of 60 has deteriorated dramatically following receipt of the booster shot, but not yet to the level seen between week 37 and week 40. The over 70’s have however seen the most dramatic fall in immune system performance between month 4 and month 5 alongside 18-29-year-olds.
The 55% boost to the immune systems of the over 80’s given by the boosters between month 3 and month 4 has all but deteriorated between month 4 and month 5. Their immune system is performing 1% better than it was in month 3 but still 54% worse than their unvaccinated counterparts.
The 73% boost to the immune systems of the 70-79-year-olds given by the boosters between month 3 and month 4 has also all but deteriorated between month 4 and month 5. Their immune system is performing 10% better than it was in month 3 but still 63% worse than their unvaccinated counterparts.
The minor boost however, given to the immune systems of everyone between the age of 30 and 59 by the boosters between month 3 and 4 has been completely decimated by the following month, whilst 18-29-year-olds have seen a 60% decline in their immune system performance between months 4 and 5.”
The 4 vitamins and supplements this doctor takes every day to strengthen her immune system https://www.cnbc.com/2022/01/30/the-4-vitamins-and-supplements-this-doctor-takes-every-day-for-a-strong-immune-system.html?__source=iosappshare%7Ccom.apple.UIKit.activity.CopyToPasteboard
I take all 4 daily and might not be here without these vital antioxidants and take magnesium as well!!
Article published 25 January 2022
Quote: Brilacidin, a COVID-19 Drug Candidate, demonstrates broad-spectrum antiviral activity against human coronaviruses OC43, 229E and NL63 through targeting both the virus and the host cell
Yanmei Hu,Hyunil Jo,William F. DeGrado,Jun Wang
First published: 25 January 2022 https://doi.org/10.1002/jmv.27616
https://onlinelibrary.wiley.com/doi/10.1002/jmv.27616
Huge! https://www.foxnews.com/politics/special-report-outlines-fresh-questions-on-what-fauci-government-knew-about-covid-origin
Crimes against humanity!!!
Sigyn Inc - $SIGY is working to cure sepsis by removing cytokines and pathogenic markers from the bloodstream. They're working to slow down this by any means. Help them find a solution by investing in it!
New Covid variant [BA.2] spreading like wildfire across UK and Scandinavia: BA.2 ‘stealth’ mutation now half of all new coronavirus cases in Denmark and rapidly pushing Omicron aside
https://www.cityam.com/new-covid-variant-is-spreading-like-wildfire-in-scandinavia-ba-2-stealth-mutation-now-half-of-all-coronavirus-cases-in-denmark-and-rapidly-pushing-omicron-aside/
https://finance.yahoo.com/news/valneva-inactivated-covid-19-vaccine-172000764.html
Quote:
Sera from 30 participants in the Phase 1/2 trial VLA2001-201 were used in a pseudovirus assay to analyze neutralization of the ancestral SARS-CoV-2 virus as well as the Delta and Omicron variants.
All 30 samples (100%) presented neutralizing antibodies against the ancestral virus and Delta variant, and 26 samples (87%) presented neutralizing antibodies against the Omicron variant. The mean fold reduction of neutralization relative to the ancestral virus was 2.7-fold for Delta and 16.7-fold for Omicron.
Investor expectations vis-à-vis VALN's coverage of Omicron must have been pretty low.
"The document also highlighted how these engineered viruses will lead to a “new era of genetic weapons” and fantasized about a bioweapon attack that could cause the “enemy’s medical system to collapse.”
https://www.orfonline.org/expert-speak/a-look-at-chinas-biowarfare-ambitions/
"Made in China 2025: The Industrial Plan that China Doesn’t Want Anyone Talking About
The administration’s biggest MIC 2025 critics have argued that the plan’s ambitious targets motivate some of the more questionable behaviors U.S. officials have accused China of, including forced technology transfer and cyber theft."
https://www.pbs.org/wgbh/frontline/article/made-in-china-2025-the-industrial-plan-that-china-doesnt-want-anyone-talking-about/
"China's Xi Jinping cements his status with historic resolution
In 2018, China scrapped the two-term limit on the presidency, effectively allowing him to remain in power for life."
https://www.bbc.com/news/world-asia-china-59229935
The companies that I have previously mentioned that I was following are all down anywhere from 3.75% - 8.6%. HGEN, BLUE, and XBI all, once again, established fresh 52 week lows again today.
"HGEN Dark Pool Trades ... Dark pool trades reported for HGEN have accounted for 41% of the total volume today. Over the past 20 days, the average dark pool volume has been 42%. Total volume in the dark pool is 467,375. The VWAP price for only the dark pool trades is 2.78. TRF Trades for HGEN are reported by dark pools to Trade Reporting Facilities and represent activity away from the mainstream or "lit" exchanges."
https://marketchameleon.com/Overview/HGEN/Stock-Price-Action/VWAP/
These dark pool trades are an excellent way for Sovereign Wealth Funds to execute their trading strategies in furtherance of their national agendas. A Market Intelligence firm should at least be able to determine if China Investment Corporation, China's Sovereign Wealth Fund, is executing these dark pool trades.
And it's a shame that these same health care professionals who were being cheered from the apartment windows of NYC residents at shift change, are now being fired because they are not vaccinated, even if they have immunity from the virus.
The biotech market is acting unusual, with too many companies on a steady decline, despite news of positive developments.
Humanigen Announces Peer-Reviewed Publication in The Journal of Medical Economics Demonstrating the Clinical and Economic Benefits of Lenzilumab
January 18 2022 - 05:55AM … Business Wire
Lenzilumab plus standard of care (SOC), resulted in an estimated cost savings of $13,190 per patient (net savings of $3,190, after an assumed price of $10,000 for lenzilumab) in those receiving remdesivir with baseline C-Reactive Protein (CRP) levels <150 mg/L, and aged <85 years
For COVID-19 patients requiring ICU admission and invasive mechanical ventilation, the average healthcare cost is $78,245 per patient
Despite increasing vaccinations, the number of COVID-19 cases, hospitalizations and deaths continues to increase, demonstrating the urgent need for both clinically effective and cost-effective variant-agnostic treatments for hospitalized patients
Humanigen, Inc. (Nasdaq: HGEN) (“Humanigen”), a clinical-stage biopharmaceutical company focused on preventing and treating an immune hyper-response called ‘cytokine storm,’ today announced a peer-reviewed publication in the Journal of Medical Economics (https://www.tandfonline.com/doi/full/10.1080/13696998.2022.2030148) citing the clinical and associated health economic benefits of lenzilumab. The publication demonstrated, in all cases, lenzilumab plus SOC improved all specified clinical outcomes compared with SOC alone. Lenzilumab plus SOC, resulted in an estimated cost savings of $13,190 per patient (net savings of $3,190, after an assumed price of $10,000 for lenzilumab) in those receiving remdesivir with baseline C-Reactive Protein (CRP) levels <150 mg/L, and aged <85 years, the primary analysis population in the fully enrolled ACTIV-5/BET-B study. In other subpopulations, per-patient savings were also observed, including those aged <85 years with baseline CRP <150mg/L with or without remdesivir (cost savings = $11,858, net cost savings = $1,858) and within the subpopulation of Black/African American patients with baseline CRP <150mg/L (cost savings = $23,154, net cost savings = $13,154).
“This publication demonstrates the opportunity to realise significant cost savings for healthcare systems, while also improving outcomes for patients,” said Dr. Adrian Kilcoyne, Chief Medical Officer, Humanigen. “With the current omicron surge, the importance of variant-agnostic and both clinically effective and cost-effective therapies is paramount.”
This peer-reviewed publication highlights the significant costs of treating hospitalized COVID-19 patients and the economic benefits of potentially improving survival without ventilation, ventilator use, time to recovery, mortality, time in the ICU, and time to invasive mechanical ventilation, which may be associated with adding lenzilumab to standard of care from the US hospital perspective.
“During these unprecedented and challenging times, we are preparing to commercialize lenzilumab as a single day treatment which is variant-agnostic and, if authorized, a driver of clinical and economic value to patients and healthcare systems,” said Edward P. Jordan, Chief Commercial Officer, Humanigen.
Omicron shows signs of easing in states hit early by contagious variant https://www.cnbc.com/2022/01/17/omicron-wave-shows-early-signs-of-easing-in-states-hit-early.html?__source=iosappshare%7Ccom.apple.UIKit.activity.CopyToPasteboard
Clinical and economic benefits of lenzilumab plus standard of care compared with standard of care alone for the treatment of hospitalized patients with COVID-19 in the United States from the hospital perspective
https://www.tandfonline.com/doi/full/10.1080/13696998.2022.2030148?src=&;
https://fb.watch/ax-Shclb36/
Biden’s competency is in question by his own team
Venture capitalists invested more money than ever into start-ups last year https://www.cnbc.com/2022/01/13/vcs-invested-more-money-than-ever-into-start-ups-last-year.html?__source=iosappshare%7Ccom.apple.UIKit.activity.CopyToPasteboard
Scientists Discover Gene That Increases Risk of Dying From Covid
Polish scientists find gene doubling risk of strong symptoms ... About 14% of Poles may have the gene, the researchers say
ByKonrad Krasuski ... January 14, 2022, 5:19 AM EST
Polish scientists have discovered a gene that they say more than doubles the risk of falling severely ill with, or even dying from Covid-19.
The Health Ministry in Warsaw expects the discovery to help identify people who are most at risk from the disease, which has already killed more than 100,000 people in Poland alone. It also plans to include genetic tests when it screens patients for potential Covid-19 infections as soon as the end of June.
https://www.bloomberg.com/news/articles/2022-01-14/gene-linked-to-severe-covid-to-provide-clues-for-those-at-risk?sref=XLA0GJqR
BUT WAIT!!!! WHAT??? ISRAEL IS LIKE 99.99% VA CC INATED, SO HOW, WHY THE VARIANT BREAKOUT?????
https://www.i24news.tv/en/news/israel/1642103315-20-cases-of-omicron-subspecies-discovered-in-israel
Great information on CDMO:
Followers
|
44
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
5468
|
Created
|
10/11/07
|
Type
|
Premium
|
Moderator Preciouslife1 | |||
Assistants toddao kgoodrich |
This board is about medical news, medical and medicine advancements from pharmaceutical and biotech companies, as
well as Universities. Company explicit news is welcomed as
well as industry news. This is an information sharing board,
where the latest and newest medical related information can
be posted and disseminated. Enjoy your board...
Scientific and Medical dedicated Search engine:
http://www.scirus.com/srsapp/
http://science.howstuffworks.com/dna.htm
http://www.biologicdrugreport.com/
Naming convention for antibody suffixes:
-ximab = chimeric
-zumab = humanized
-(~z)umab = fully human
FDA and CDC sites:
FDA what's new site: http://www.fda.gov/ohrms/dockets/ac/acwhatsnew.htm
http://www.accessdata.fda.gov/scripts/cder/drugsatfda/
http://www.fda.gov/
http://www.fda.gov/cder/
http://news.google.com/news?q=FDA&hl=en&rls=DGUS,DGUS:2006-15,DGUS:en&um=1&ie=UTF-8&....
http://www.cdc.gov/
Researching sites:
http://clearstation.etrade.com/
http://www.breakouttrading.net/index2/index.php
http://moneycentral.msn.com/investor/home.asp
http://www.superstarinvestor.com/directory.html
http://www.nasdaq.com/
http://www.ddmachine.com/default.asp
http://new.stockwatch.com/
http://www.edgar-online.com/
Educational sites:
http://www.investopedia.com/
http://www.qwoter.com/college/
http://biotech-profits.org/
http://www.hardrightedge.com/wheel/tcrules1.htm
http://www.therapeuticsdaily.com/news/channel.cfm?channelID=28
http://www.medicalnewstoday.com/sections/genetics/
http://www.medicalnewstoday.com/sections/biology-biochemistry/
http://content.nejm.org/current.shtml
http://www.sciencedaily.com/
Some T/A sites:
http://www.americanbulls.com/
http://www.askresearch.com/
http://www.stockta.com/
http://www.stockconsultant.com./
http://www.investorshub.com/boards/read_msg.asp?message_id=297509
http://www.ttrader.com/dirttime.php
http://www.otcbb.com/asp/Info_Center.asp
http://bigcharts.marketwatch.com/
Find out if your stock is on the SHO List
http://www.buyins.net/tools/short_list.php?src=1,7,9
Understanding Level 11-http://www.hotstockmarket.com/forums/showthread.php?t=14938
OTCBB Biggest Gainers (%)http://www.stockhouse.com/mostactives/index.asp?type=winners&exchange=OTCBB
OTC Biggest Declinershttp://www.stockhouse.com/mostactives/index.asp?type=losers&exchange=OTCBB
OTC Biggest Volume Gainers http://www.stockhouse.com/mostactives/index.asp?type=mostactives&exchange=OTCBB
Technical Indicators http://stockcharts.com/school/doku.php?id=chart_school:technical_indicators
Screeners:
http://finviz.com/screener.ashx?v=111&f=cap_microover,geo_usa,sh_curvol_o100,sh_insttrans_o20,sh_price_o1,sh_short_u5,ta_rsi_ob70&ft=4&r=21 From Stock Seasonality Site.
http://www.marketscreen.com/c/pcquote/default.asp
http://moneycentral.msn.com/investor/finder/deluxestockscreen.aspx?query=Institutional+Ownership+Up+....
http://www.secform4.com/index.php
http://screen.morningstar.com/StockSelector.html
http://www.stockfetcher.com
http://investorideas.com/
http://www.wallstreettape.com/
http://findarticles.com/p/articles/mi_pwwi/is_200603/ai_n1610669
4
http://find.thestreet.com/cgi-bin/texis/tscsection/?k=Technology&sec=Technology&submenu=news....
Filings Sites:
http://www.pinksheets.com/
http://www.otcbb.com
http://www.gsionline.com/support/formtypes.html
http://www.coordinatedlegal.com/SecretaryOfState.html
http://www.searchsystems.net/list.php?nid=398
SEC FORM EXPLANATIONS
http://www.sec.gov/about/forms/secforms.htm
http://www.briefing.com/GeneralInfo/Features/LearningCenter/edu_SEC_Documents.htm
http://www.sec.gov/index.htm
To see how and about the SEC rules, regulations and cases involving stock manipulators.
SEC REALTIME FILINGS
http://www.nasdaq.com/asp/quotes_sec.asp?mode=&page=&symbol=QQQQ&symbol=&symbol=&....
http://home.businesswire.com/portal/site/home/index.jsp?front_door=true&headlineSearchConfigBO=v....
BOARD RULES:
The main objective for this moderated thread is to keep it free of posts which do not add value to the discussion of the stocks, the latest medical news, and information, while keeping the board balanced, clean, on-topic with due diligence kept up to date.
All posts here should stay focused on medical news and information.
Pro and con debate is encouraged as long as the opinions are kept on a mature level, with the omission of personal attacks,
violations of IHUB rules and basic civility.
Personal attacks, personal issues, political innuendo, spamming, duplicate posts of same subject matter, redundancy, obvious bashing, blatant pumping, irrelevant off topic subject matter, advertising, arguing, feeding and promoting bashers of other IHUB sites will be strictly prohibited.
Posts which the moderators feel violate these rules will be removed without question or debate.
If you are willing to cooperate and co~exist with other posters in this environment within the guidelines laid out, then welcome and have a great time posting and learning.
Please Note: Please add links to websites and information whenever they are available for accuracy and informational purposes.
Plus, I am not an MD, but rather a longtime biotech/pharma investor and former Quant analyst. So, if I can answer any questions relating to medical information, I will, and cede to any medical professionals whom are better equipped to answer those inquiries.
Thank you....PL1
Posts Today
|
0
|
Posts (Total)
|
5468
|
Posters
|
|
Moderator
|
|
Assistants
|
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |